Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLO: VTP-200 for Low-grade HPV-related Cervical Lesions
NCT04607850Phase 2Completed
- Sponsor
- Barinthus Biotherapeutics
- Start
- Mar 2021
- Primary completion
- Jan 2024
- Modality
- Viral Vector Vaccines, Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of MVA-HPV in human papillomavirus infection and cervical intraepithelial neoplasia (CIN) (9 arms), sponsored by Barinthus Biotherapeutics. Primary endpoint: Incidence of adverse events to measure safety and reactogenicity at 12 months. Started Mar 2021; status: completed.
02
Drugs
MVA-HPV
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT04607850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04607850.